CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment

Last updated: March 14, 2019
Project Number: OP0532-000
Product Line: Optimal Use
Result type: Report

Glaucoma is a leading cause of blindness. A range of surgical interventions exist for treating glaucoma, including a group of procedures commonly called micro-invasive or minimally invasive glaucoma surgery (MIGS). It has been noted that, across Canada, there is a growing demand for MIGS, as well as a rise in the use of MIGS procedures. At the same time, the cost of MIGS implantable devices can be considerable and inconsistencies appear to exist in some jurisdictions regarding coverage under public health insurance plans.

CADTH, in collaboration with Ontario Health (Quality), undertook an Optimal Use project to assess the clinical effectiveness, safety, cost-effectiveness, patient perspectives and experiences, ethical issues, and implementation issues around MIGS devices and procedures for adults with glaucoma.